Last Updated : May 2, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Verquvo | vericiguat | Heart failure | Reimburse with clinical criteria and/or conditions | Complete | ||
Rinvoq | upadacitinib | ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Sohonos | palovarotene | Fibrodysplasia Ossificans Progressiva | Reimburse with clinical criteria and/or conditions | Complete | ||
Koselugo | selumetinib | Neurofibromatosis type 1 | Reimburse with clinical criteria and/or conditions | Complete | ||
Skyrizi | risankizumab | Crohn's disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Rukobia | fostemsavir | Human immunodeficiency virus type 1 (HIV-1) | Reimburse with clinical criteria and/or conditions | Complete | ||
N/A | dapagliflozin | Chronic kidney disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Lynparza | olaparib | gBRCAm, HER2-negative high-risk early breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
N/A | rivaroxaban | Venous thromboembolic events (VTE) | Reimburse with clinical criteria and/or conditions | Active | ||
Imfinzi and Imjudo | durvalumab and tremelimumab | unresectable hepatocellular carcinoma | Reimburse with clinical criteria and/or conditions | Complete |